The EPO granted and published patent EP3854869A1 to Orizuru Therapeutics, Inc. for insulin-producing cells, classified under IPC C12N 5/071. The patent covers therapeutic applications for diabetes treatment (A61P 3/10) and cell-based therapies. The designation extends to all 35+ European contracting states including Germany, France, UK, Italy, Spain, and others.

Patent publications are informational notices establishing intellectual property rights. Competitors developing similar cell therapy products for diabetes should review the patent claims to assess potential licensing needs or design-around requirements. The patent grant does not impose compliance deadlines or reporting obligations on third parties.